BeiGene reports its first annual profit, but the stock price plummeted.

The capital market is really interesting. In previous years of annual losses, stock prices kept rising based on expectations. Now that the company is finally profitable with significant growth, the stock price has plummeted because the revenue growth rate is only “40%.” Have they not considered the previous base? Revenue is now in the hundreds of millions, and with a 40% growth rate, do they still expect over 100% growth once reaching hundreds of millions? Innovative drugs have indeed taken a big hit recently.